RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Grand Pharmaceutical Group - Stock

Grand Pharmaceutical Group P/E 2024

Grand Pharmaceutical Group P/E

7.97

Ticker

512.HK

ISIN

BMG210A71016

WKN

A0Q8LD

As of Jul 9, 2024, Grand Pharmaceutical Group's P/E ratio was 7.97, a -14.94% change from the 9.37 P/E ratio recorded in the previous year.

The Grand Pharmaceutical Group P/E history

Grand Pharmaceutical Group Aktienanalyse

What does Grand Pharmaceutical Group do?

China Grand Pharmaceutical and Healthcare Holdings Ltd is an innovative company in the healthcare and pharmaceutical industry in China. The company was founded in 1997 and is headquartered in Wuhan, Hubei Province. China Grand Pharma specializes in developing, manufacturing, and distributing high-quality medications, medical devices, and services. The company has multiple subsidiaries involved in various areas of the healthcare and pharmaceutical industry. China Grand Pharma’s main business areas include the production and sale of synthetic drugs, traditional Chinese medicines, biopharmaceuticals, veterinary medicine, and medical devices and equipment. The company has a high level of technological expertise in synthetic drug development and has a team of experienced scientists and researchers. China Grand Pharma has continuously invested in research and development to develop innovative and effective medications that meet the needs of patients in China and worldwide. The traditional Chinese medicine segment is another important area of China Grand Pharma’s business. The company holds a leading position in the market and offers a wide range of products made from natural plant extracts and traditional Chinese medicines. Biopharmaceuticals, based on innovative technologies such as recombinant DNA technology or stem cell research, are another important focus of China Grand Pharma. The company is able to develop and manufacture high-quality biopharmaceuticals that can be used for the prevention and treatment of serious diseases. China Grand Pharma is also a major player in the veterinary medicine market and offers a wide range of products for the health of livestock and pets. The company has a high level of technological expertise and has an extensive portfolio of products for the diagnosis, prevention, and treatment of animal diseases. The company also offers a wide range of medical devices and equipment for healthcare in hospitals and clinics. China Grand Pharma provides a variety of products, from diagnostic instruments to surgical tools. Overall, China Grand Pharmaceutical and Healthcare Holdings Ltd is one of the leading companies in the healthcare and pharmaceutical industry in China. The company has a comprehensive range of products and is able to provide high-quality products and services for a variety of applications and needs. China Grand Pharma is highly committed to researching and developing medications and technologies that can improve healthcare in China and enhance the lives of patients worldwide. The company has a strong presence in the Chinese market and has a well-established distribution infrastructure that allows it to distribute its products and services in China and beyond. Grand Pharmaceutical Group ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Grand Pharmaceutical Group's P/E Ratio

The Price to Earnings (P/E) Ratio of Grand Pharmaceutical Group is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Grand Pharmaceutical Group's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Grand Pharmaceutical Group is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Grand Pharmaceutical Group’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Grand Pharmaceutical Group stock

What is the price-to-earnings ratio of Grand Pharmaceutical Group?

The price-earnings ratio of Grand Pharmaceutical Group is currently 7.97.

How has the price-earnings ratio of Grand Pharmaceutical Group changed compared to last year?

The price-to-earnings ratio of Grand Pharmaceutical Group has increased by -14.94% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Grand Pharmaceutical Group high compared to other companies?

Yes, the price-to-earnings ratio of Grand Pharmaceutical Group is high compared to other companies.

How does an increase in the price-earnings ratio of Grand Pharmaceutical Group affect the company?

An increase in the price-earnings ratio of Grand Pharmaceutical Group would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Grand Pharmaceutical Group affect the company?

A decrease in the price-earnings ratio of Grand Pharmaceutical Group would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Grand Pharmaceutical Group?

Some factors that influence the price-earnings ratio of Grand Pharmaceutical Group are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Grand Pharmaceutical Group pay?

Over the past 12 months, Grand Pharmaceutical Group paid a dividend of 0.14 HKD . This corresponds to a dividend yield of about 2.97 %. For the coming 12 months, Grand Pharmaceutical Group is expected to pay a dividend of 0.16 HKD.

What is the dividend yield of Grand Pharmaceutical Group?

The current dividend yield of Grand Pharmaceutical Group is 2.97 %.

When does Grand Pharmaceutical Group pay dividends?

Grand Pharmaceutical Group pays a quarterly dividend. This is distributed in the months of July, July, July, July.

How secure is the dividend of Grand Pharmaceutical Group?

Grand Pharmaceutical Group paid dividends every year for the past 8 years.

What is the dividend of Grand Pharmaceutical Group?

For the upcoming 12 months, dividends amounting to 0.16 HKD are expected. This corresponds to a dividend yield of 3.32 %.

In which sector is Grand Pharmaceutical Group located?

Grand Pharmaceutical Group is assigned to the 'Health' sector.

Wann musste ich die Aktien von Grand Pharmaceutical Group kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Grand Pharmaceutical Group from 6/27/2024 amounting to 0.26 HKD, you needed to have the stock in your portfolio before the ex-date on 6/6/2024.

When did Grand Pharmaceutical Group pay the last dividend?

The last dividend was paid out on 6/27/2024.

What was the dividend of Grand Pharmaceutical Group in the year 2023?

In the year 2023, Grand Pharmaceutical Group distributed 0.11 HKD as dividends.

In which currency does Grand Pharmaceutical Group pay out the dividend?

The dividends of Grand Pharmaceutical Group are distributed in HKD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Grand Pharmaceutical Group

Our stock analysis for Grand Pharmaceutical Group Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Grand Pharmaceutical Group Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.